C4 Therapeutics (CCCC) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 27.8% versus a gain of 15.3%. Over five years, FENC leads with a +15.7% price change compared with -93.6% for CCCC. Fennec Pharmaceuticals is the larger company by market cap ($372.8 million vs $350.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | FENC |
|---|---|---|
| Share price | $2.85 | $10.63 |
| Market cap | $350.62M | $372.76M |
| 1-day change | +1.06% | +2.61% |
| YTD return | +49.21% | +38.05% |
| 1-year return | +27.80% | +15.29% |
| 5-year return | -93.57% | +15.67% |
| Forward P/E | — | 11.21 |
| EPS (TTM) | $-0.91 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $13.25 |
| 52-week low | $1.69 | $5.65 |
| Distance from 52-week high | -44.87% | -19.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +367.72% | +66.23% |
| Average volume | 2.39M | 193.13K |
| Shares outstanding | 123.03M | 35.07M |
| Employees | 104 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed FENC by 12.5 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
CCCC vs FENC FAQ
Which is bigger, C4 Therapeutics or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $372.76M compared with $350.62M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or FENC?
CCCC returned +27.80% over the past 12 months, compared with +15.29% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.